S-1/A: Salarius & Decoy Merger Advances Amid Nasdaq Delisting Threat

Salarius Pharmaceuticals and Decoy Therapeutics are progressing with their merger and a new financing round, while Salarius faces imminent Nasdaq delisting for non-compliance with listing rules.

Summary

• Salarius Pharmaceuticals, Inc. (SLRX) and Decoy Therapeutics Inc. are moving forward with a two-step merger, with Decoy becoming a wholly-owned subsidiary of Salarius.
• The merger is conditioned on Salarius raising at least $6.0 million in a 'Qualified Financing' and maintaining its Nasdaq listing.
• Salarius is offering 10,794,765 shares of common stock or pre-funded warrants, along with Series A and Series B common warrants, and representative warrants, at an assumed combined public offering price of $0.7411 per share.
• Net proceeds from the offering are estimated at approximately $6.5 million, or $7.6 million if the underwriters' option is fully exercised.
• Salarius faces Nasdaq delisting due to non-compliance with the $1.00 minimum bid price and the $2.5 million stockholders' equity requirements, with an extended deadline to regain compliance by late August 2025.
• Post-merger, Salarius legacy stockholders will retain approximately 7.6% and Decoy stockholders will own approximately 92.4% of the combined company, before accounting for financing dilution.
• Decoy's proprietary IMP3ACT platform leverages machine learning and AI for peptide conjugate drug discovery, focusing on infectious diseases and oncology.
• Decoy's lead program, a pan-Coronavirus prophylactic, has shown promising preclinical results and aims for an IND filing in the first half of 2026.
• The combined company plans to integrate Salarius' SP-3164 compound into Decoy's platform to create novel peptide-based PROTACs (P-PROTACs) for metastatic colorectal cancer.
• Salarius has curtailed its SP-3164 development and closed its SP-2577 Ewing sarcoma trial to conserve cash, but continues to support an MDACC-sponsored trial for SP-2577 in blood disorders.
• Decoy's financial condition raises substantial doubt about its ability to continue as a going concern, having incurred net losses since inception and an accumulated deficit of $26.0 million as of March 31, 2025.

Sentiment

Score: 3

Explanation: The sentiment is predominantly negative due to Salarius' severe financial distress, imminent Nasdaq delisting threat, and the significant dilution experienced by its legacy shareholders. While the merger with Decoy brings a promising preclinical pipeline and non-dilutive funding, the immediate risks and uncertainties surrounding regulatory compliance, capital requirements, and the early stage of Decoy's assets outweigh the potential long-term positives.

Positives

• The merger with Decoy Therapeutics provides Salarius with a new, innovative preclinical pipeline focused on peptide conjugate therapeutics, leveraging AI/ML for drug discovery.
• Decoy's IMP3ACT platform has demonstrated broad-spectrum antiviral activity against human coronaviruses, including SARS-CoV-2 variants, and paramyxoviruses in preclinical studies.
• The lead pan-Coronavirus prophylactic program (DCOY-101) has shown in vitro and in vivo efficacy, with an IND filing planned for the first half of 2026.
• Decoy has secured significant non-dilutive funding from organizations like The Gates Foundation, BARDA, Google, and NVIDIA, reducing reliance on equity financing for early-stage development.
• The combined company aims to address significant unmet medical needs in infectious diseases and oncology, with potential for multi-indication therapeutics.
• The Series A Warrants include a one-time reset of the exercise price in the event of a reverse stock split, offering some protection to warrant holders.
• The Series B Preferred Stock includes mandatory redemption provisions using proceeds from Salarius' at-the-market equity program and equity line of credit, which could benefit holders.

Negatives

• Salarius faces significant Nasdaq delisting risk due to non-compliance with minimum bid price and stockholders' equity requirements, with a tight deadline of late August 2025.
• The common warrants will not be exercisable until stockholder approval is obtained, and there is no guarantee this approval will be secured, rendering them potentially valueless.
• Decoy's financial condition raises substantial doubt about its ability to continue as a going concern, with recurring net losses and an accumulated deficit of $26.0 million as of March 31, 2025.
• Salarius has curtailed its own SP-3164 development and closed the SP-2577 Ewing sarcoma clinical trial to conserve cash, indicating severe financial constraints prior to the merger.
• The combined company will experience immediate and substantial dilution for new investors purchasing securities in this offering, with a dilution of $0.46 per share.
• The post-merger entity will be required to satisfy all Nasdaq's initial listing criteria and complete the initial listing process, which is uncertain and could lead to further delays or delisting.
• The Series B Warrants include a zero cash exercise option, meaning Salarius will not receive additional funds upon their exercise, limiting future capital inflow from these warrants.
• The anti-dilution price protection for Preferred Stockholders in subsequent dilutive financings could further dilute common stockholders.

Risks

• The merger may be completed even if material adverse changes affect Salarius or Decoy, potentially impacting the combined company's market price.
• Nasdaq may delist the combined company's securities if it fails to regain compliance with listing rules or meet initial listing standards, severely limiting liquidity and capital raising ability.
• Stockholders may experience substantial additional dilution from future sales of shares under existing equity line of credit (ELOC) and at-the-market (ATM) agreements.
• The historical unaudited pro forma financial information may not accurately represent the combined company's future results.
• Restrictions in the Merger Agreement may prevent Salarius and Decoy from pursuing more favorable business combinations with other parties.
• Salarius cannot guarantee stockholder approval for the conversion of Preferred Stock into common stock, which could materially harm operations.
• The lack of a public market for Decoy's capital stock makes its valuation difficult, potentially leading to Salarius paying more than fair market value.
• The combined company may face securities class action litigation, diverting management attention and incurring significant costs.
• Failure to complete the merger would result in Salarius incurring substantial costs and potentially lead to dissolution and liquidation.
• The combined company will need to raise additional capital, which may cause further dilution or impose restrictive covenants.
• Decoy's product candidates are in preclinical stages, and there is no guarantee they will lead to marketable products or successfully complete clinical trials.
• Reliance on third parties for clinical trials and manufacturing poses risks of delays, non-compliance, and increased costs.
• Decoy's novel drug discovery approach, leveraging AI/ML, is unproven and may not lead to marketable products, and is subject to unique risks related to technology and infrastructure.
• Inability to obtain or protect intellectual property rights for product candidates could impair competitive advantage.
• Third-party claims of intellectual property infringement could delay development and commercialization efforts.
• Loss of key management or scientific personnel could materially harm the business.
• Compliance with healthcare fraud and abuse laws, false claims laws, and health information privacy laws is complex and non-compliance could lead to significant penalties.
• Business interruptions from pandemics or natural disasters could delay R&D efforts.

Future Outlook

The combined company, to be renamed Decoy Therapeutics, Inc., will focus on developing innovative peptide conjugates using its IMP3ACT platform, initially targeting infectious diseases and oncology. It plans to file an IND for its pan-Coronavirus prophylactic in the first half of 2026 and aims to advance another transformative program to IND-enabling status within two years. The company will also conduct a thorough review of Salarius' legacy small molecule program, SP-2577, in mid-2025. Operations are expected to be funded through August 2026 with existing cash, Gates Foundation funds, and proceeds from this offering, assuming the merger closes.

Management Comments

• Salarius' board of directors believed that, as a result of arms length negotiations with Decoy, Salarius and its management team negotiated the most favorable implied value and equity split for its stockholders that Decoy was willing to agree to.
• Salarius' board of directors believed that the merger is more favorable to its stockholders than the potential value that might have resulted from other strategic options available to Salarius, which would likely be a liquidation of Salarius and the distribution of any available cash if the Merger is not consummated.
• Decoy believes its integration with Salarius expands the combined company's opportunities to create an additional novel class of peptide conjugates, specifically, peptide-based proteolysis targeting chimeras (P-PROTACs), utilizing the Salarius compound SP-3164 as an important building block.
• Decoy believes the IMP3ACT platform has the potential to change the economics of antiviral drug development by addressing multiple high health burden viruses and preparing the world for emerging future threats with a single drug.
• Decoy believes that there is a reasonable probability that the rationally designed fusion inhibitor will show similar activity against Measles and Nipah in in vitro pseudotype assays, though this cannot be confirmed until experiments are performed.
• Decoy believes its target selection strategy will maximize the return on investment from the IMP3ACT platform by allowing Decoy to efficiently advance paradigm creating therapeutics across its peptide conjugate, peptide drug conjugate and peptide-PROTAC molecules.
• Decoy believes its continuous manufacturing technology will lead to a single continuous operation to produce a very complex molecule, overall improvement of synthesis speed, in-process analytical and quality checks, and simplicity of the overall process.

Industry Context

The merger positions the combined entity, Decoy Therapeutics, at the forefront of peptide conjugate drug discovery, a rapidly emerging therapeutic modality exemplified by successful diabetes and weight loss treatments. By leveraging machine learning and AI, Decoy aims to decrease the complexity and accelerate the development of these innovative drugs, initially focusing on infectious diseases and oncology. The integration of Salarius' SP-3164 compound into Decoy's P-PROTAC platform represents an expansion into a novel class of targeted protein degraders, potentially addressing 'undruggable' targets and improving safety. This strategy aligns with broader industry trends towards precision medicine, advanced manufacturing techniques, and the use of AI in drug development, while also addressing the ongoing global need for broad-spectrum antiviral treatments.

Comparison to Industry Standards

• Decoy's IMP3ACT platform aims to decrease the complexity of peptide conjugate development, positioning itself as a leader in this advancing drug class, similar to the success seen with drugs like Ozempic, Wegovy, Mounjaro, and ZepBound.
• Decoy's continuous manufacturing process aims to reduce synthesis time for peptide conjugates from several months (typical at a standard CDMO) to days or hours, significantly faster than traditional drug development processes.
• Decoy's goal of manufacturing 30g of active pharmaceutical ingredient (API) for a new therapeutic candidate in 30 days aims to meet or exceed the 100-day goal for vaccine manufacturing, setting a high benchmark for speed.
• Decoy's pan-Coronavirus inhibitor program targets a significant unmet medical need among immune-suppressed patients, offering a prophylactic alternative where current options like Paxlovid have drug-drug interaction concerns and antibody-based prophylactics (e.g., Evusheld, Pemgarda) face efficacy loss due to viral evolution.
• Decoy's broad respiratory antiviral program aims to treat Flu/COVID/RSV with a single peptide conjugate, an unprecedented approach compared to existing single-virus antiviral treatments like Tamiflu for influenza or Paxlovid for SARS-CoV-2.
• In oncology, Decoy's GPCR-targeted conjugates for colorectal cancer aim to identify new cell membrane targets for precision medicine, addressing the limited biomarker-driven options currently available (e.g., trastuzumab deruxtecan for HER2-positive mCRC, which applies to only 3-5% of patients).

Management Changes

Corporate Governance

Legal Proceedings

• Salarius is not currently a party to any legal proceedings the outcome of which would individually or in the aggregate have a material adverse effect on its business, financial condition, or results of operations.
• Decoy is not currently a party to any legal proceedings that, in the opinion of its management, are likely to have a material adverse effect on its business.

Related Party Transactions

• Frederick (Rick) Pierce, Decoy's CEO and founder, has an outstanding Demand Note ($55,555 principal + $9,817 accrued interest as of March 31, 2025) which he has agreed to exchange for shares of Salarius Series B Preferred Stock.
• Barbara Hibner (Decoy's CSO) and Peter Marschel (Decoy's CBO) have non-interest bearing notes ($48,000 and $29,950 respectively) that will remain outstanding for 12 months beyond the Merger Closing.
• Approximately $140,000 of non-interest bearing notes held by Decoy's founders and officers will remain outstanding post-Merger Closing, with maturity dates extended by 12 months.

Stakeholder Impact

• Shareholders of Salarius will experience significant dilution in ownership and voting interest in the combined company (retaining approximately 7.6% pre-financing dilution).
• Shareholders of Decoy will become the majority owners of the combined company (approximately 92.4% pre-financing dilution), gaining public market access for their equity.
• New investors in the offering will face immediate and substantial dilution.
• Employees and management of both companies will see changes in roles and reporting structures, with Decoy's senior management taking key positions in the combined entity.
• Creditors of Decoy will have a majority of their outstanding non-convertible notes exchanged for Series B Preferred Stock, with some notes being paid off from offering proceeds.
• The continued Nasdaq listing is critical for all shareholders, as delisting would severely impact liquidity and investment attractiveness.
• The anti-dilution provisions for Preferred Stockholders could impact the value for common stockholders in future dilutive financings.

Next Steps

• Salarius intends to effect a reverse stock split shortly after the consummation of this offering and Merger Closing, and in any event, prior to its deadline for regaining Nasdaq minimum bid price compliance by the end of August 2025.
• Salarius intends to commence the Nasdaq initial listing process for the post-transaction entity following the consummation of this financing and the Merger Closing.
• Salarius will call a special stockholder meeting to approve the conversion of the Preferred Stock into common stock (Conversion Proposal), a new equity incentive plan, and a reverse stock split (if necessary and advisable).
• Salarius intends to register the issuance of the shares of Salarius common stock underlying the Preferred Stock within 60 days of the Merger Closing.
• Decoy plans to file an Investigational New Drug (IND) application for its pan-Coronavirus fusion inhibitor program in the first half of 2026.
• Decoy intends to continue pursuing non-dilutive funding and a development partner for its pan-Coronavirus program's clinical development.
• The combined company plans to integrate Salarius' SP-3164 compound into Decoy's peptide engineering platform to create P-PROTACs, with an initial focus on metastatic colorectal cancer.
• The combined company intends to conduct a thorough review of the SP-2577 small molecule program in mid-2025.
• Decoy aims to advance one additional transformative program to IND-enabling status within two years.
• Decoy intends to pursue platform manufacturing designation from the FDA to rapidly scale-up peptide-conjugate drug candidates.

Key Dates

Recommendation

The filing presents a highly speculative investment. While the merger with Decoy Therapeutics offers a promising, AI-driven preclinical pipeline in high-demand therapeutic areas (infectious diseases, oncology), Salarius' severe financial distress and imminent Nasdaq delisting threat create substantial near-term risk. The significant dilution for existing Salarius shareholders and the early-stage nature of Decoy's assets mean that any potential upside is long-term and highly uncertain. The success of the combined entity hinges on successful clinical development, regulatory approvals, and the ability to secure further capital, all of which are fraught with risk. A 'hold' recommendation acknowledges the potential for future value creation from Decoy's platform but emphasizes the significant current uncertainties and risks that make a 'buy' premature and a 'sell' potentially missing out on a high-risk, high-reward scenario if the merger and pipeline succeed.

Keywords

Biotechnology, Pharmaceuticals, Merger, SEC Filing, Nasdaq Delisting, Peptide Conjugates, AI Drug Discovery, Oncology, Infectious Diseases, Warrants, Capital Raise, Preclinical Development, SP-3164, SP-2577, Decoy Therapeutics, Salarius Pharmaceuticals